{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:42:19Z","timestamp":1789040539021,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["FOSSIS 2017-2-289663"],"award-info":[{"award-number":["FOSSIS 2017-2-289663"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10067-020-05499-1","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T08:02:56Z","timestamp":1604995376000},"page":"2233-2242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4062-9412","authenticated-orcid":false,"given":"Juan M.","family":"Mejia-Vilet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael A.","family":"G\u00f3mez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3242-0125","authenticated-orcid":false,"given":"Cristino","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Ang\u00e9lica","family":"M\u00e9ndez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roque A.","family":"Comunidad-Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-1298","authenticated-orcid":false,"given":"Norma O.","family":"Uribe-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5051-0389","authenticated-orcid":false,"given":"Carlos A.","family":"Nu\u00f1ez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7227-484X","authenticated-orcid":false,"given":"Luis E.","family":"Morales-Buenrostro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"5499_CR1","unstructured":"Mejia-Vilet JM, Rovin BH (2019) Chapter 59: Epidemiology and management of lupus nephritis. In: Wallace D, Hahn B (ed) Dubois\u2019 lupus erythematosus and related syndromes, 9th edn. Elsevier, pp 59_1\u201359_18"},{"key":"5499_CR2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ki.2012.409","volume":"83","author":"LH Wu","year":"2013","unstructured":"Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, Liu G, Zhao MH (2013) Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 83:715\u2013723","journal-title":"Kidney Int"},{"key":"5499_CR3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/0961203317692419","volume":"26","author":"JM Mej\u00eda-Vilet","year":"2017","unstructured":"Mej\u00eda-Vilet JM, C\u00f3rdova-S\u00e1nchez BM, Uribe-Uribe NO, Correa-Rotter R, Morales-Buenrostro LE (2017) Prognostic significance of renal vascular pathology in lupus nephritis. Lupus 26:1042\u20131050","journal-title":"Lupus"},{"key":"5499_CR4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D (2018) Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 13:300\u2013317","journal-title":"Clin J Am Soc Nephrol"},{"key":"5499_CR5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","volume":"10","author":"E Gavriilaki","year":"2019","unstructured":"Gavriilaki E, Anagnostopoulos A, Mastellos DC (2019) Complement in thrombotic microangiopathies: unraveling Ariadne\u2019s thread into the labyrinth of complement therapeutics. Front Immunol 10:337","journal-title":"Front Immunol"},{"key":"5499_CR6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785\u2013797","journal-title":"Nat Immunol"},{"key":"5499_CR7","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","volume":"46","author":"A Klos","year":"2009","unstructured":"Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, K\u00f6hl J (2009) The role of the anaphylatoxins in health and disease. Mol Immunol 46:2753\u20132766","journal-title":"Mol Immunol"},{"key":"5499_CR8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","volume":"164","author":"H Watanabe","year":"2000","unstructured":"Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS (2000) Modulation of renal disease in MRL\/ lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164:786\u2013794","journal-title":"J Immunol"},{"key":"5499_CR9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1523-1755.2004.00371.x","volume":"65","author":"MK Elliott","year":"2004","unstructured":"Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS (2004) Effects of complement factor D deficiency on the renal disease of MRL\/lpr mice. Kidney Int 65:129\u2013138","journal-title":"Kidney Int"},{"key":"5499_CR10","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4049\/jimmunol.175.3.1947","volume":"175","author":"L Bao","year":"2005","unstructured":"Bao L, Osawe I, Haas M, Quigg RJ (2005) Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 175:1947\u20131955","journal-title":"J Immunol"},{"key":"5499_CR11","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/eji.200526327","volume":"35","author":"L Bao","year":"2005","unstructured":"Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ (2005) C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 35:2496\u20132506","journal-title":"Eur J Immunol"},{"key":"5499_CR12","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/art.1780290905","volume":"29","author":"HM Belmont","year":"1986","unstructured":"Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S (1986) Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 29:1085\u20131089","journal-title":"Arthritis Rheum"},{"key":"5499_CR13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.1780350907","volume":"35","author":"JP Buyon","year":"1992","unstructured":"Buyon JP, Tamerius J, Belmont HM, Abramson SB (1992) Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 35:1028\u20131037","journal-title":"Arthritis Rheum"},{"key":"5499_CR14","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/art.1780390716","volume":"39","author":"S Manzi","year":"1996","unstructured":"Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, Medsger TA Jr, Ramsey-Goldman R (1996) Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 39:1178\u20131188","journal-title":"Arthritis Rheum"},{"key":"5499_CR15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.amjms.2017.01.005","volume":"353","author":"D Song","year":"2017","unstructured":"Song D, Guo WY, Wang FM, Li YZ, Song Y, Yu F, Zhao MH (2017) Complement alternative pathway\u2019s activation in patients with lupus nephritis. Am J Med Sci 353:247\u2013257","journal-title":"Am J Med Sci"},{"key":"5499_CR16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-017-1470-2","volume":"19","author":"M Martin","year":"2017","unstructured":"Martin M, Smolag KI, Bj\u00f6rk A, Gullstrand B, Okr\u00f3j M, Leffler J, J\u00f6nsen A, Bengtsson AA, Blom AM (2017) Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus. Arthritis Res Ther 19:266","journal-title":"Arthritis Res Ther"},{"key":"5499_CR17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.humimm.2013.04.030","volume":"74","author":"RM Nisihara","year":"2013","unstructured":"Nisihara RM, Magrini F, Mocelin V, Messias-Reason IJ (2013) Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients. Hum Immunol 74:907\u2013910","journal-title":"Hum Immunol"},{"key":"5499_CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3349\/ymj.2003.44.1.75","volume":"44","author":"SH Kim","year":"2003","unstructured":"Kim SH, Jeong HJ (2003) Glomerular C4d deposition indicates in situ classic complement pathway activation, but is not a marker for lupus nephritis activity. Yonsei Med J 44:75\u201380","journal-title":"Yonsei Med J"},{"key":"5499_CR19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0961203307083279","volume":"16","author":"SJ Li","year":"2007","unstructured":"Li SJ, Liu ZH, Zen CH, Wang QW, Wang Y, Li LS (2007) Peritubular capillary C4d deposition in lupus nephritis different from antibody-mediated renal rejection. Lupus 16:875\u2013880","journal-title":"Lupus"},{"key":"5499_CR20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0961203311415561","volume":"20","author":"N Sato","year":"2011","unstructured":"Sato N, Ohsawa I, Nagamachi S, Ishii M, Kusaba G, Inoshita H, Toki A, Horikoshi S, Ohi H, Matsushita M, Tomino Y (2011) Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus 20:1378\u20131386","journal-title":"Lupus"},{"key":"5499_CR21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0961203311422093","volume":"21","author":"I Batal","year":"2012","unstructured":"Batal I, Liang K, Bastacky S, Kiss LP, McHale T, Wilson NL, Paul B, Lertratanakul A, Ahearn JM, Manzi S, Kao AH (2012) Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study. Lupus 21:13\u201326","journal-title":"Lupus"},{"key":"5499_CR22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/0886022X.2012.743916","volume":"35","author":"OZ Sahin","year":"2013","unstructured":"Sahin OZ, Gurses S, Tasli F, Yavas H, Ersoy R, Uzum A, Cirit M (2013) Glomerular C4d staining can be an indicator of disease activity in lupus nephritis. Ren Fail 35:222\u2013225","journal-title":"Ren Fail"},{"key":"5499_CR23","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/art.23662","volume":"58","author":"D Cohen","year":"2008","unstructured":"Cohen D, Koopmans M, Kremer Hovinga IC, Berger SP, van Groningen MR, Steup-Beekman GM, de Heer E, Bruijn JA, Bajema IM (2008) Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 58:2460\u20132469","journal-title":"Arthritis Rheum"},{"key":"5499_CR24","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/0961203310368409","volume":"19","author":"Y Shen","year":"2010","unstructured":"Shen Y, Chen XW, Sun CY, Dai M, Yan YC, Yang CD (2010) Association between anti-\u03b22 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus 19:1195\u20131203","journal-title":"Lupus"},{"key":"5499_CR25","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1681\/ASN.2014050429","volume":"26","author":"JS Chua","year":"2015","unstructured":"Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, Bruijn JA, BAjema IM, Cohen D (2015) Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol 26:2239\u20132247","journal-title":"J Am Soc Nephrol"},{"key":"5499_CR26","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1681\/ASN.V481499","volume":"4","author":"GB Appel","year":"1994","unstructured":"Appel GB, Pirani CL, D\u2019Agati V (1994) Renal vascular complications of systemic. J Am Soc Nephrol 4:1499\u20131515","journal-title":"J Am Soc Nephrol"},{"key":"5499_CR27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, D\u2019Agati VD, Ferrario F, Haas M, Jennette JC, Joh K, Nast CC, No\u00ebl LH, Rijnink EC, Roberts ISD, Seshan SV, Sethi S, Fogo AB (2018) Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93:789\u2013796","journal-title":"Kidney Int"},{"key":"5499_CR28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semnephrol.2015.08.006","volume":"35","author":"DJ Birmingham","year":"2015","unstructured":"Birmingham DJ, Hebert LA (2015) The complement system in lupus nephritis. Semin Nephrol 35:444\u2013454","journal-title":"Semin Nephrol"},{"key":"5499_CR29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","volume":"22","author":"AP Manderson","year":"2004","unstructured":"Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22:431\u2013456","journal-title":"Annu Rev Immunol"},{"key":"5499_CR30","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1681\/ASN.2005040373","volume":"16","author":"SE Wenderfer","year":"2005","unstructured":"Wenderfer SE, Ke B, Hollmann TJ, Wetsel RA, Lan HY, Braun MC (2005) C5a receptor deficiency attenuates T cell function and renal disease in MRL lpr mice. J Am Soc Nephrol 16:3572\u20133582","journal-title":"J Am Soc Nephrol"},{"key":"5499_CR31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.molimm.2008.12.004","volume":"46","author":"SE Wenderfer","year":"2009","unstructured":"Wenderfer SE, Wang H, Ke B, Wetsel RA, Braun MC (2009) C3a receptor deficiency accelerates the onset of renal injury in the MRL\/lpr mouse. Mol Immunol 46:1397\u20131404","journal-title":"Mol Immunol"},{"key":"5499_CR32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000186513","volume":"59","author":"Y Kusunoki","year":"1991","unstructured":"Kusunoki Y, Akutsu Y, Itami N, Tochimaru H, Nagata Y, Takekoshi Y, Sagawa A, Kataoka Y, Nagasawa S (1991) Urinary excretion of terminal complement complexes in glomerular disease. Nephron 59:27\u201332","journal-title":"Nephron"},{"key":"5499_CR33","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2215\/CJN.02790313","volume":"8","author":"SJ Gou","year":"2013","unstructured":"Gou SJ, Yuan J, Wang C, Zhao MH, Chen M (2013) Alternative Complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol 8:1884\u20131891","journal-title":"Clin J Am Soc Nephrol"},{"key":"5499_CR34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","volume":"22","author":"EG de Jorge","year":"2011","unstructured":"de Jorge EG, Macor P, Paix\u00e3o-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering M (2011) The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 22:137\u2013145","journal-title":"J Am Soc Nephrol"},{"key":"5499_CR35","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","volume":"110","author":"P Redecha","year":"2007","unstructured":"Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G (2007) Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody\u2013induced fetal injury. Blood 110:2423\u20132431","journal-title":"Blood"},{"key":"5499_CR36","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1084\/jem.182.6.1807","volume":"182","author":"S Saadi","year":"1995","unstructured":"Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL (1995) Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 182:1807\u20131814","journal-title":"J Exp Med"},{"key":"5499_CR37","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","volume":"52","author":"SS Pierangeli","year":"2005","unstructured":"Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J (2005) Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52:2120\u20132124","journal-title":"Arthritis Rheum"},{"key":"5499_CR38","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","volume":"68","author":"K Oku","year":"2009","unstructured":"Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, Yasuda S, Koike T (2009) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68:1030\u20131035","journal-title":"Ann Rheum Dis"},{"key":"5499_CR39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","volume":"107","author":"KA Breen","year":"2012","unstructured":"Breen KA, Seed P, Parmar K, Moore GW, Stuart-Smith SE, Hunt BJ (2012) Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 107:423\u2013429","journal-title":"Thromb Haemost"},{"key":"5499_CR40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2017.06.014","volume":"156","author":"JH Rand","year":"2017","unstructured":"Rand JH, Wu XX, Wolgast LR, Lei V, Conway EM (2017) A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. Thromb Res 156:119\u2013125","journal-title":"Thromb Res"},{"key":"5499_CR41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","volume":"49","author":"N Kello","year":"2019","unstructured":"Kello N, El Khoury L, Marder G, Furie R, Zapantis E, Horowitz DL (2019) Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum 49:74\u201383","journal-title":"Semin Arthritis Rheum"},{"key":"5499_CR42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1681\/ASN.2010060647","volume":"22","author":"L Bao","year":"2011","unstructured":"Bao L, Haas M, Quigg RJ (2011) Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 22:285\u2013295","journal-title":"J Am Soc Nephrol"},{"key":"5499_CR43","doi-asserted-by":"crossref","first-page":"e1002079","DOI":"10.1371\/journal.pgen.1002079","volume":"7","author":"J Zhao","year":"2011","unstructured":"Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, Kaufman KM, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A, Glenn SB, Alarc\u00f3n-Riquelme ME, BIOLUPUS Network, GENLES Network, Pons-Estel BA, Harley JB, Bae SC, Bang SY, Cho SK, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Kimberly RP, Edberg JC, Brown EE, Alarcon GS, Petri MA, Ramsey-Goldman R, Vil\u00e1 LM, Reveille JD, James JA, Gilkeson GS, Kamen DL, Freedman BI, Anaya JM, Merrill JT, Criswell LA, Scofield RH, Stevens AM, Guthridge JM, Chang DM, Song YW, Park JA, Lee EY, Boackle SA, Grossman JM, Hahn BH, Goodship THJ, Cantor RM, Yu CY, Shen N, Tsao BP (2011) Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 7:e1002079","journal-title":"PLoS Genet"},{"key":"5499_CR44","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/rheumatology\/kes218","volume":"51","author":"F Wang","year":"2012","unstructured":"Wang F, Yu F, Tan Y, Song D, Zhao M (2012) Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. Rheumatology (Oxford) 51:2269\u20132277","journal-title":"Rheumatology (Oxford)"},{"key":"5499_CR45","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ki.2011.497","volume":"81","author":"D Cohen","year":"2012","unstructured":"Cohen D, Colvin RB, Daha MR, Drachenberg CB, Haas M, Nickeleit V, Salmon JE, Sis B, Zhao MH, Bruijn JA, Bajema IM (2012) Pros and cons for C4d as a biomarker. Kidney Int 81:628\u2013639","journal-title":"Kidney Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05499-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05499-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05499-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T22:16:07Z","timestamp":1621030567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05499-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5499"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05499-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"23 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was conducted in compliance with the Helsinki declaration. The study was approved by the local research and ethics boards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}